Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TST003 in Locally Advanced or Metastatic Solid Tumors
NCT05731271Phase 2Active, not recruiting
- Sponsor
- Transcenta
- Start
- Feb 2023
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tst003 in solid tumor, colorectal adenocarcinoma, sponsored by Transcenta. Started Feb 2023; status: active, not recruiting.
02
Drugs
tst003
03
Conditions
solid tumorcolorectal adenocarcinoma
Beyond the preview
Go deeper on NCT05731271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731271.